treatment and treatment options Archives

Abstract Number: 2580 • ACR/ARHP Annual Meeting 2018
Predicting Treatment Persistence and Non-Persistence of Newly Initiated TNF Inhibitor Therapy in Ankylosing Spondylitis Patients: A Gender Comparison
Theresa Hunter¹, Atul A. Deodhar², Rebecca Bolce¹, Krista Schroeder¹ and David Sandoval Calderon¹, ¹Eli Lilly and Company, Indianapolis, IN, ²Oregon Health & Science U, Portland, OR
Background/Purpose: The purpose of this study was to compare treatment patterns in the 2 years following the initiation of TNF inhibitor (TNFi) in AS patients.Methods:…
Abstract Number: 2581 • ACR/ARHP Annual Meeting 2018
Comparing Treatment Patterns of Non-Radiographic Axial Spondyloarthritis Patients in the United States and Europe
Theresa Hunter¹, David Sandoval Calderon¹, Steve Lobosco², Rachel Moon², Gary Milligan³ and Rebecca Bolce¹, ¹Eli Lilly and Company, Indianapolis, IN, ²Adelphi Real World, Macclesfield, United Kingdom, ³Adelphi Real World, Macclesfield,, United Kingdom
Background/Purpose: To compare TNF inhibitor (TNFi) use and switching patterns among patients with nr-axSpA in the United States (US) and Europe (EU). Methods: Data from…
Abstract Number: 79 • Pediatric Rheumatology Symposium 2017
Predicting Colchicine Response in Patients with Undefined Autoinflammatory Diseases
Jonathan S. Hausmann^1,2, Burcu Guven², Edwin Anderson³ and Fatma Dedeoglu², ¹Rheumatology, Beth Israel Deaconess Medical Center, Boston, MA, ²Rheumatology, Boston Children's Hospital, Boston, MA, ³Division of Immunology, Boston Children's Hospital, Boston, MA
Background/Purpose: Autoinflammatory diseases (AIDs) are a rare group of illnesses characterized by unprovoked episodes of fever and systemic inflammation. An understanding of their pathophysiology has…
Abstract Number: 2478 • ACR/ARHP Annual Meeting 2016
Impact of Poor Prognostic Factors on Treatment Decisions in Clinical Practice in Patients with Rheumatoid Arthritis: Findings from a US Observational Cohort
LR Harrold¹, E Alemao², HJ Litman³, SE Connolly⁴, S Kelly², W Hua³, L Rosenblatt², S Rebello⁵ and JM Kremer⁶, ¹University of Massachusetts Medical School, Worcester, MA, ²Bristol-Myers Squibb, Princeton, NJ, ³Corrona, Southborough, MA, ⁴Department of Immunology and Inflammation, Bristol-Myers Squibb, Princeton, NJ, ⁵Epidemiology, Corrona, Southborough, MA, ⁶Albany Medical College and The Center for Rheumatology, Albany, NY
Background/Purpose: Poor prognostic factors can determine the extent of disease progression, disability and treatment outcomes in patients (pts) with RA. It is currently unknown whether…
Abstract Number: 437 • ACR/ARHP Annual Meeting 2015
Is Mode of Action Important When Switching Biologic Monotherapy in Rheumatoid Arthritis? Drug Adherence Results from the Swedish Ssatg Registry
Tanja Schjødt Jørgensen¹, Carl Turesson², Meliha C. Kapetanovic³, Martin Englund^4,5, Aleksandra Turkiewicz⁴, Robin Christensen¹, Henning Bliddal¹, Pierre Geborek³ and Lars Erik Kristensen¹, ¹The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen, Denmark, ²Lund University, Rheumatology, Dept. of Clinical Sciences,, Malmö, Sweden, ³Department of Clinical Sciences Lund, Section of Rheumatology Lund University and Skåne University Hospital, Lund, Sweden, ⁴Orthopedics, Department of Clinical Sciences Lund, Lund University, Lund, Sweden, ⁵Clinical Epidemiology Unit, Orthopedics, Dept of Clinical Sciences Lund, Lund University, Lund, Sweden
Background/Purpose: About 30% of patients receiving biologic therapy do not have concomitant conventional synthetic DMARDs (csDMARDs). Little is known about the role of different mode…
Abstract Number: 2102 • ACR/ARHP Annual Meeting 2015
Higher Persistence and Adherence with Combination Therapy with Tumor Necrosis Factor Inhibitor+Methotrexate Combination Versus Triple Therapy in US Veterans with Rheumatoid Arthritis
Brian Sauer¹, Chia-Chen Teng², Jianwei Leng³, Ted R. Mikuls⁴, Jeffrey R. Curtis⁵, Bradley S. Stolshek⁶, Derek Tang⁶ and Grant W. Cannon⁷, ¹IDEAS Center and Division of Epidemiology, HSR&D SLC VA Medical Center and University of Utah, Salt Lake City, UT, ²HSR&D SLC VA Medical Center and University of Utah, Salt Lake City, UT, ³Internal Medicine Division of Epidemiology, HSR&D SLC VA Medical Center and University of Utah, Salt Lake City, UT, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶Amgen, Inc., Thousand Oaks, CA, ⁷Division of Rheumatology, Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT

Background/Purpose: Randomized controlled trials in RA have reported efficacy with both triple therapy (methotrexate [MTX] + hydroxychloroquine [HCQ] + sulfasalazine [SSZ]) and tumor necrosis factor…
Abstract Number: 940 • ACR/ARHP Annual Meeting 2014
Reducing Therapy in Rheumatoid Arthritis Patients in Ongoing Remission
Judith Haschka^1,2, Jürgen Rech³, Matthias Englbrecht¹, Stephanie Finzel¹, Michaela Reiser¹, Axel J. Hueber¹, Arnd Kleyer¹, Hans-Peter Tony⁴, Martin Fleck⁵, Karin Manger⁶, Wolfgang Ochs⁷, Jörg Wendler⁸, Hanns-Martin Lorenz⁹, Hubert Nüßlein¹⁰, Rieke Alten¹¹, Winfried Demary¹² and Georg Schett¹, ¹Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany, ²Department of Internal Medicine 2, The VINFORCE Study Group, St. Vincent Hospital Vienna, Vienna, Austria, ³Internal Medicine 3, Rheumatology and Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁴Department of Internal Medicine 2, University Hospital Würzburg, Würzburg, Germany, ⁵Department of Rheumatology and Clinical Immunology, Asklepios Medical Center Bad Abbach, Bad Abbach, Germany, ⁶Rheumatology Practice Bamberg, Bamberg, Germany, ⁷Rheumatology Practice Bayreuth, Bayreuth, Germany, ⁸Rheumatology Practice Erlangen, Erlangen, Germany, ⁹Department of Internal Medicine 5, Division of Rheumatology, University of Heidelberg, Heidelberg, Germany, ¹⁰Rheumatology Practice Nuremberg, Nuremberg, Germany, ¹¹Schlosspark-Klinik, University Medicine Berlin, Berlin, Germany, ¹²Rheumatolgy Practice Hildesheim, Hildesheim, Germany
Background/Purpose: Due to improved therapeutic management a steadily increasing number of rheumatoid arthritis (RA) patients reach stable remission of disease. Data on withdrawal of medication…
Abstract Number: 1587 • ACR/ARHP Annual Meeting 2013
Continuous Variables Of Treatment Interventions In Patients Diagnosed With Systemic Lupus Erythematosus Among Commercially and Medicaid Insured Populations In The U.S
Hong Kan¹, Saurabh Nagar¹, Jeetvan Patel¹, Anna Oh², Daniel J. Wallace³ and Charles T. Molta⁴, ¹GlaxoSmithKline, Research Triangle Park, NC, ²University of California San Francisco, San Francisco, CA, ³Cedars-Sinai Medical Center, Los Angeles, CA, ⁴GlaxoSmithKline, Philadelphia, PA
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that affects multiple organs including the heart, lungs, kidneys, joints, and the nervous system. Standard…

Abstracts tagged "treatment and treatment options"